Literature DB >> 2952492

Modulatory role of vasopressin in secretion of atrial natriuretic polypeptide in conscious rats.

H Itoh, K Nakao, T Yamada, N Morii, S Shiono, A Sugawara, Y Saito, M Mukoyama, H Arai, G Katsuura.   

Abstract

To investigate whether vasopressin is involved in the secretory mechanism of atrial natriuretic polypeptide (ANP), effects of arginine-vasopressin (AVP) administered iv on plasma ANP levels were studied in conscious, unrestrained rats. The administration of 100 ng and 1 microgram of AVP caused a dose-dependent increase of the plasma ANP level, which was blocked by a V1-receptor antagonist of AVP, and was attenuated by 5 ml blood volume reduction before the stimulation. The injection of less than 10 ng of AVP induced no significant effects on ANP secretion. However, the administration of 5 ng of AVP significantly enhanced ANP secretion induced by intravascular volume expansion with 3 ml saline infusion. These results suggest the possible physiological significance of AVP as a modulator rather than a direct stimulator of ANP secretion from the heart.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2952492     DOI: 10.1210/endo-120-5-2186

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  3 in total

1.  [Postoperative therapy using human atrial natriuretic peptide in cases of valve replacement].

Authors:  T Maeda; M Kitamura; A Kawai; M Hachida; S Aomi; M Endo; H Koyanagi; Y Sakomura; N Matsuda; H Kasanori
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-12

2.  Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells.

Authors:  H Itoh; R E Pratt; V J Dzau
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

3.  Chronic blockade of endogenous atrial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acetate-salt-hypertensive rats.

Authors:  H Itoh; K Nakao; M Mukoyama; T Yamada; K Hosoda; G Shirakami; N Morii; A Sugawara; Y Saito; S Shiono
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.